BFM
YMAB

Boothbay Fund Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Boothbay Fund Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-693,693
Closed -$3.13M – 2220
2025
Q2 		$3.13M Hold
693,693
– – 0.06% 404
2025
Q1 		$3.07M Hold
693,693
– – 0.08% 332
2024
Q4 		$5.43M Buy
693,693
+136,264
+24% +$1.66M 0.13% 222
2024
Q3 		$7.33M Buy
557,429
+188,069
+51% +$2.38M 0.17% 155
2024
Q2 		$4.46M Buy
369,360
+22,849
+7% +$308K 0.11% 261
2024
Q1 		$5.63M Sell
346,511
-347,583
-50% -$4.68M 0.11% 194
2023
Q4 		$4.73M Buy
694,094
+678,548
+4,365% +$3.92M 0.12% 218
2023
Q3 		$84.7K Buy
+15,546
New +$90.5K ﹤0.01% 1586
2021
Q4 		– Sell
-7,682
Closed -$219K – 2278
2021
Q3 		$219K Sell
7,682
-253
-3% -$7.97K 0.01% 1516
2021
Q2 		$268K Buy
+7,935
New +$255K 0.01% 1353

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's YMAB Position: Q3 2025 in Review

Boothbay Fund Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 693,693 shares — an estimated $3.13M sold.

Boothbay Fund Management first reported a position in YMAB in Q2 2021 and held it in 10 quarters. The position peaked at $7.33M in Q3 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Boothbay Fund Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 693,693 Y-mAbs Therapeutics shares in Q3 2025, an estimated $3.13M.
  • Boothbay Fund Management first reported a position in Y-mAbs Therapeutics in Q2 2021 and held it in 10 quarters.
  • Boothbay Fund Management's Y-mAbs Therapeutics position peaked at $7.33M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.